Results 21 to 30 of about 1,701 (184)

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review [PDF]

Viruses
Lenacapavir (LEN) is the first-in-class capsid inhibitor that inhibits HIV capsid function in vitro with picomolar activity. LEN has been approved for the treatment of HIV in combination with other antiretroviral agents (ARVs), as well as for the ...
Nicolas A. Margot, Christian Callebaut
doaj   +2 more sources

Awareness, knowledge, perception and behavioral risk predictors of acceptability of long-acting injectable lenacapavir HIV pre-exposure prophylaxis in Ghana: a cross-sectional study [PDF]

AIDS Research and Therapy
Long-acting injectable HIV pre-exposure prophylaxis (PrEP), particularly lenacapavir, has demonstrated near-complete efficacy, yet its public health impact depends on community awareness, knowledge and acceptance.
Ebenezer Senu, Cornelia Quainoo Donkor, Success Acheampomaa Oppong, Daniel Dzemedo Nouwati, Emmanuel Ntori, George Kyei Agyen, Alfred Effah   +6 more
doaj   +2 more sources

Drivers of Vertical HIV Transmission in Sub‐Saharan Africa and the Impact and Cost‐Effectiveness of Targeted and Universal Lenacapavir Pre‐Exposure Prophylaxis [PDF]

Journal of the International AIDS Society
Introduction Eliminating vertical HIV transmission remains a major public health priority, particularly in sub‐Saharan Africa (SSA), which accounted for 83% of global paediatric HIV acquistions in 2024.
Anna Yakusik, Magdalene K. Walters, Deepak Mattur, Savvy Brar, Leigh F. Johnson, Gesine Meyer‐Rath, Lise Jamieson, Angela Mushavi, John Stover, Mary Mahy   +9 more
doaj   +2 more sources

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval [PDF]

Antimicrobial Agents and Chemotherapy
There is limited data on lenacapavir (LEN) use, the newest capsid inhibitor, in observational settings. We describe population characteristics and pharmaco-virological outcomes of people with HIV-1 (PWH) who initiated LEN-based treatment.
Charlotte Charpentier, Thomas Montrouge, Marc Wirden, Véronique Avettand-Fenoel, Camille Tumiotto, Pantxika Bellecave, Audrey Rodallec, Elisabeth Garnier, Djeneba Fofana, Sidonie Lambert-Niclot, Brigitte Montès, Marie-Laure Chaix, Caroline Charre, Pierre Gantner, Magali Bouvier-Alias, Enagnon Kazali Alidjinou, Pauline Coulon, Gilbert Mchantaf, Agnès Beby-Defaux, Elodie Alessandri-Gradt, Alice Moisan, Quentin Le Hingrat, Minh Lê, Constance Delaugerre, Anne-Geneviève Marcelin, Gilles Peytavin, Vincent Calvez, Diane Descamps   +27 more
doaj   +2 more sources

A theoretical study of the atropodiastereomerism of Lenacapavir

Structural Chemistry
Abstract This paper presents a theoretical study of Lenacapavir, a promising drug for HIV prevention, with the dual objective of reproducing experimental results of the R a and predicting the properties of the less stable atropodiastereomer, S
Ibon Alkorta, José Elguero
openaire   +2 more sources

Implementation of long-acting injectable PrEP at a Latine community organization: protocol for a mixed-methods, hybrid type 3 implementation-effectiveness study [PDF]

BMJ Open
Introduction Latine individuals account for a disproportionate share of new HIV diagnoses in the USA, yet uptake of HIV pre-exposure prophylaxis (PrEP) remains critically low in this population.
Tonia Poteat, Richard Barfield, Melissa K Cutshaw, Iris Navarro, Taylor Krajewski, Kayla W Kilpatrick, Mehri S McKellar   +6 more
doaj   +2 more sources

Lenacapavir as pre-exposure prophylaxis for HIV prevention. [PDF]

Cochrane Database Syst Rev
Globally, there are 1.3 million new HIV infections annually, with a disproportionate burden on young women and girls, especially in sub-Saharan Africa (63% of new infections). Despite the demonstrated effectiveness of pre-exposure prophylaxis (PrEP), global uptake remains low, reaching only 16.5% of the UNAIDS 2025 target.
Ebrahim S, Gloeck N, Adam Z, Tatz G, Nel J, Sinxadi PZ, Dawood H, Kredo T, Cohen K.   +8 more
europepmc   +3 more sources

Lenacapavir: una revisión bibliográfica del fármaco que promete erradicar el VIH desde la profilaxis [PDF]

Ciencia & Salud
Describir las características clínicas, la eficacia y los retos de accesibilidad del lenacapavir, un inhibidor de la cápside viral del VIH con aplicaciones en tratamiento y profilaxis preexposición (PrEP).
Ivo Heyerdahl-Viau
doaj   +2 more sources

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations

Viruses, 2022
Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase ...
Maria E. Cilento, Yee Tsuey Ong, Philip R. Tedbury, Stefan G. Sarafianos   +3 more
doaj   +2 more sources

Lenacapavir: A Potential Game Changer for HIV Prevention in the Americas, If the Game Is Played Equitably

The Lancet Regional Health Americas
Summary: Lenacapavir, a first in class long-acting capsid inhibitor has near 100% efficacy in preventing HIV. As such, it has the potential to curb the rising HIV incidence in Latin America, a region with stark intra- and inter-country PrEP uptake ...
Valeria D Cantos, Carlos del Rio, Beatriz Grinsztejn   +2 more
exaly   +3 more sources